Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced positive data from two late-stage studies, ISLEND-1 and ISLEND-2, ...

For decades scientists have recognized that human immunodeficiency virus (HIV) is a formidable viral pathogen. After years of probing work and extensive experimentation, a Yale research team has ...

The combination of islatravir and lenacapavir targets multiple stages of HIV-1 replication, potentially offering people with ...

In an important discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human immunodeficiency ...

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for remission without therapy. For years, HIV has been synonymous not only with ...

A new Northwestern Medicine study has uncovered a surprising molecular link between HIV-1 and a protein fragment associated with Alzheimer's disease, according to findings published in the Proceedings ...

University of Delaware professor Juan Perilla (right), is co-author of a new paper that reveals a previously unknown structural role for integrase, a key HIV protein, earlier in the virus' life cycle ...

A long-standing belief about HIV has quietly shaped how scientists think about the virus. For decades, researchers described the virus as hiding in a “latent reservoir,” a group of infected cells that ...